Source: European Medicines Agency (EU) Revision Year: 2025 Publisher: Purpose Pharma International AB, Grev Turegatan 13b, 114 46 Stockholm, Sweden
Attrogy 250 mg film-coated tablets.
| Pharmaceutical Form |
|---|
|
Film-coated tablet (tablet). Light orange, capsule shape, biconvex coated tablet, engraved “D250” on one side and plain on the other side. The tablet is 6.35 mm in width and 14.29 mm in length. |
Each film-coated tablet contains 250 mg diflunisal.
Excipient(s) with known effect: Each tablet contains 60 micrograms sunset yellow (E110).
For the full list of excipients, see section 6.1.
| Active Ingredient |
|---|
|
Diflunisal is a potent stabiliser of tetrameric transthyretin (TTR), which effectively stabilises the tetramer against dissociation to the TTR monomers which are responsible for amyloidosis pathology. |
| List of Excipients |
|---|
|
Microcrystalline cellulose (E460) (PH 101) |
HDPE bottle with polypropylene child-resistant tamper-evident screw cap with a liner. Pack size of 100 film-coated tablets.
Purpose Pharma International AB, Grev Turegatan 13b, 114 46 Stockholm, Sweden
EU/1/25/1929/001
| Drug | Countries | |
|---|---|---|
| ATTROGY | Austria, Estonia, Lithuania |
© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.